Comparative Pharmacology
Head-to-head clinical analysis: ATHENTIA NEXT versus DASETTA 1 35.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ATHENTIA NEXT versus DASETTA 1 35.
ATHENTIA NEXT vs DASETTA 1/35
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Levonorgestrel is a progestin that inhibits ovulation and alters cervical mucus, reducing sperm penetration. Ethinyl estradiol suppresses gonadotropin release, preventing follicular development.
Combination of an estrogen (ethinyl estradiol) and a progestin (norethindrone). Suppresses gonadotropin-releasing hormone (GnRH) from the hypothalamus, reducing luteinizing hormone (LH) and follicle-stimulating hormone (FSH) secretion from the pituitary, thereby inhibiting ovulation. Additionally, induces changes in cervical mucus (impenetrability to sperm) and endometrium (reduced likelihood of implantation).
Not established. ATHENTIA NEXT is not a recognized pharmaceutical agent. Consult official prescribing information.
One tablet orally once daily, each containing 1 mg norethindrone acetate and 35 mcg ethinyl estradiol.
None Documented
None Documented
Terminal elimination half-life: 12-15 hours in healthy adults; clinically relevant for once-daily dosing.
Norethindrone: 5-14 hours (mean 8 hours); ethinyl estradiol: 10-20 hours (mean 14 hours). Clinical context: steady-state achieved within 5-7 days.
Renal excretion of unchanged drug: 60-70%; fecal/biliary elimination: 20-30%; hepatic metabolism accounts for <10%.
Renal (55-60% as metabolites, 25-30% as unchanged drug and conjugates), biliary/fecal (30-35% as metabolites).
Category C
Category C
Oral Contraceptive
Oral Contraceptive